Infratil shares on watch after CDC Data Centres’ valuation climbs

The Infratil Ltd (ASX: IFT) share price is on watch after the company revealed a 23.6% quarterly jump in the independent valuation of its CDC Data Centres interest, reaching a midpoint of A$18.5 billion. The uplift was fuelled by rapid growth in CDC’s contracted capacity to over 1GW and a bigger pipeline out to FY40.

What did Infratil report?

• CDC’s independent valuation rose by A$3.5 billion during the quarter to a midpoint of A$18.5 billion.
• Infratil’s 49.72% share in CDC is now valued at A$9,213 million, up from A$7,454 million in March 2026.
• Contracted capacity at CDC increased to over 1GW, including a new 555MW contract and further expansion in New Zealand.
• Leasable operating capacity lifted by 90MW to 550MW, with the pipeline to FY40 now 3.9GW, up from 2.6GW.
• Net debt at CDC increased to A$5,976 million, supporting its accelerated build program.

What else do investors need to know?

CDC’s build program is running faster to deliver the surge in contracted capacity expected by FY29, with under-construction leasable capacity doubling this quarter to 810MW. The future pipeline was extended to FY40, adding an extra 1.3GW of future build capacity, particularly targeting Australian markets to meet pressing customer demand. The independent valuation also factored in a 25 basis point increase in the risk-free rate, partly offsetting the positive cashflow momentum. CDC recently issued a A$1 billion hybrid capital bond and received a Moody’s Baa2 (Stable) credit rating, supporting funding diversification.

What’s next for Infratil?

Looking ahead, Infratil expects CDC’s growth momentum to continue, with ongoing investment in data centre capacity aimed at supporting new and existing contracts out to FY40. By rolling forward pipeline disclosures and redefining capacity metrics to focus on leasable, revenue-generating potential, Infratil is aiming to match evolving customer needs and capitalise on data centre sector demand. As CDC accelerates expansion across Australia and New Zealand, investors can anticipate regular updates as projects move from planning to operation. Interest rate and funding trends will remain key influences.

Infratil share price snapshot

Over the past 12 months, Infratil shares have risen 23%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen 3% over the same period.

View Original Announcement

The post Infratil shares on watch after CDC Data Centres’ valuation climbs appeared first on The Motley Fool Australia.

More reading

• Genesis Minerals proposes Vault merger to create gold powerhouse
• Capricorn Metals hits upper end of FY26 gold production guidance, advances project expansions
• Regis Resources hits top end of FY26 guidance
• Greatland Resources posts record FY26 gold output
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.